DelveInsight’s Glaucoma Pipeline Insight, 2022 report provides deep insights into 70+ companies and 70+ pipeline drugs in the glaucoma pipeline landscape.”
It includes the glaucoma pipeline Drug profiles, including clinical and non-clinical stage products. It also includes the evaluation of glaucoma therapeutics by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.
Key takeaways from the GlaucomaPipeline report
- DelveInsights glaucoma The pipeline analysis reveals the space with 70+ active players working to develop 70+ pipeline therapies.
- That glaucoma The pipeline report includes its detailed analysis of various drugs at different stages of clinical development including phase II, I, pre-clinical and discovery.
- Glaucoma pipeline companies include Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia SA de CV, pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma , Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug Inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience Inc., Eyebiotech Limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., and many others.
- Glaucoma pipeline therapies include QLS-101, NCX 470, H-1337, CKD-351, Visomitin, D930, GAL-101, CLX-OPH-56, CBT-007, TA-A002, VT-1041, LL-BMT1, Nyxol, PDP – 716 , BZ371A, MAN-01, D565, K-232, ONL1204, AGN-193408, H-1337, WB007, AKB-9778, OTX-TIC, JV-GL1, OTX-TPa,…